PolTREG SA develops and commercializes patented TREG methods. It engages in the research, development, implementation, and commercialization of T-regulatory lymphocytes and using their growth method for clinical use to treat type 1 diabetes. The company was founded in 2015 by Piotr Trzonkowski, Malgorzata Mysliwiec, Wojciech Tadeusz Kakol and Natalia Maria Marek Trzonkowska and is headquartered in Gdansk, Poland.